Form 4 for OVID Ovid Therapeutics Inc.
Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-23 · accession 0001311404-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-02 | 2026-02-26 | OVID | Rona Jeffrey A | CBFO | A - Grant | $0.00 | +68.1K | 156.3K | +77% | $0 |
| D | 2026-03-02 | 2026-02-23 | OVID | Rona Jeffrey A | CBFO | S - Sale | $1.45 | -8,541 | 88.2K | -9% | -$12.4K |
| D | 2026-03-02 | 2026-02-26 | OVID | Rona Jeffrey A | CBFO | A - Grant | $0.00 | +408.8K | 408.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-26 | A | A | 68,125 | $0.00 | 156,313 | D | — | — | (F4) Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date. (F5) Each RSU represents a contingent right to receive one share of Common Stock. |
| 2 | Common | Common Stock | 2026-02-23 | S | D | 8,541 | $1.45 | 88,188 | D | — | — | (F1) Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. (F2) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F3) Includes 28,756 shares acquired under the Issuer's employee stock purchase plan. |
| 3 | Derivative | Employee Stock Option (Right to Buy) | 2026-02-26 | A | A | 408,750 | $0.00 | 408,750 | D | $1.65 · — to 2036-02-25 | 408,750 Common Stock | (F6) The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date. |